IBCN annual meeting included a session on novel therapies and outcome measures in clinical trials, featuring a presentation by Dr. Gautier Marcq discussing the benefit of whole-pelvis radiation for ...
First, doubling down on FDA reform is essential. The key center reviewing drugs has 5,910 employees, only a fraction of which are directly involved in drug review. By trimming bureaucracy and ...
The Bruton's tyrosine kinase inhibitor tolebrutinib is reportedly the first agent to show benefit in patients with nonrelapsing secondary progressive MS.